Balyasny Asset Management Acquires 5.33% Stake in Ovid Therapeutics Inc.

On May 15, 2026, Balyasny Asset Management L.P. (BAM) filed a Schedule 13G indicating a new 5.33% stake in Ovid Therapeutics Inc. (OVID). The reporting persons, including Dmitry Balyasny, BAM GP LLC, and related entities, collectively reported beneficial ownership of 7,029,223 shares of common stock. This total includes 5,533,073 shares held directly by investment funds Atlas Diversified Master Fund, Ltd. and Atlas Private Holdings (Cayman) Ltd, as well as 1,496,150 shares issuable upon the exercise of Series B and Prefunded Warrants. The exercise of these warrants is subject to beneficial ownership blockers of 4.99% and 9.99%, respectively. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This position represents a significant increase from zero shares previously reported, crossing the 5% threshold required for beneficial ownership disclosure.